Ernexa Therapeutics Inc. · NASDAQ:ERNA
Ernexa Therapeutics — Investor Presentation (October 2026)
19 slides from Ernexa Therapeutics's investor presentation, Oct 15, 2026
Slide 1: Modulating Immune System to Target Cancer Through Synthetic iMSC Therapy
Modulating Immune System to Target Cancer Through Synthetic Induced Mesenchymal Stromal Cell (iMSC) Therapy October 2026 ernexatx.com Investor Presentation Nasdaq: ERNA
Slide 2: Safe Harbor Statement
S a f e H a r b o r S t a t em e n t This presentation (this “Presentation”) and any oral statements made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, de
Slide 3: A Highly Experienced Leadership Team
A H i g h l y E x p er i en c e d L e a d e r s h i p Te a m Sanjeev Luther, MBA; President and CEO: Deborah Wild, Head of CMC and Operations: 25–30 years in drug development and strategy; 35+ years of experience spanning biopharma, raised >$100M, led a clinical-stage manufacturing, operations, and
Slide 4: Providing Hope
OUR MISSION Providing Hope We are developing innovative cell therapies to bring new treatment possibilities to people facing difficult-to-treat cancers Starting with ovarian cancer Copyright © 2026. Ernexa Therapeutics Inc. 4
Slide 5: The Ernexa Opportunity
T h e E r n e xa O p p o r t u n i t y Engineered induced mesenchymal stromal cell (iMSC) therapy platform with compelling preclinical data and a clear path towards clinical trials TECHNOLOGY PLATFORM LEAD ASSET Synthetic iMSCs ERNA-101 Immune Activation Within Tumors Designed to Turn “Cold” Tumors
Slide 6: A Pipeline in a Product: Driving Next-Generation iMSC Therapy Across Solid Tumors
A Pip el in e in a Pro du ct : D r i v i n g N ex t - G e n e ra t i o n i M S C T h e r a p y Ac r o s s S o l i d T u m o r s Upcoming Asset Indication Combinations Preclinical Phase 1 Phase 2 Milestones Platinum- IND Submission Pembrolizumab by Q4 2026 Resistant + Ovarian Cancer FIH Study by Beva
Slide 7: Mechanism of Action of ERNA-101: Trojan Horse for Cancer
M e c h a n i s m o f A c t i o n o f E R N A -1 0 1 : U t i l i z i n g t h e I n t r i n s i c Tu m o r - H o m i n g Ab i l i t y o f M S C s t o C r e a t e a Tr o j a n H o r s e f o r C a n c e r Untreated Tumor (Cold) ERNA-101-Treated Tumor (Hot) 1 ERNA-101 selectively infiltrates and homes i
Slide 8: ERNA-101: Engineered iMSC Therapy Addressing Shortcomings of Other Approaches
E R N A -1 0 1 : E n g i n e e r e d i M S C B a s e d T h e r a p y D e s i g n e d t o A d d r e s s t h e S hor tc omi ng s of Other Th erap eu tic App ro ac hes TREATMENT APPROACH KEY LIMITATION ERNA-101’S APPROACH Small-molecule Targeted delivery; Designed to limit systemic Systemic exposure an
Slide 9: Lead Indication: Platinum-Resistant Ovarian Cancer (PROC)
Lea d In di cat io n: P l a t i n u m - R e s i s t a n t O v a r i a n Ca n c e r ( P RO C ) PROC is a subset of recurrent ovarian cancer, defined by disease progression within six months after completing platinum-based chemotherapy ~17,000 ~25% patients U.S. patients with PROC* Affected in first r
Slide 10: ERNA-101 Treatment Leads to Substantial Accumulation of IL-7_IL-15 and T-Cell Infiltration
E R N A -1 0 1 Tr e a t m e n t L e a d s t o S u b s t a n t i a l A c c u m u l a t i o n o f I L -7 _ I L -1 5 & Sig ni fic an t In c rease i n T-Cell I nfil tra ti on i nt o th e TM E Ovarian tumor-bearing mice treated with PBS, GFP-iMSC or ERNA-101 (IL-7_IL-15-iMSCs) CYTOKINE EXPRESSION IN TUMO
Slide 11: ERNA-101 + Anti-PD-1 Demonstrated Complete Tumor Clearance and 100% Survival
I P E R N A -1 0 1 + An t i - P D -1 D e mo n s t r a t e d C o mp l e t e Tu m o r C l e a r a n c e a n d 1 0 0 % S u r v i v a l i n a n O v a r i a n C a n c er M o d el ERNA-101 + anti-PD-1 in a preclinical ID8LUC-OVA syngeneic mouse model 100% Survival through follow-up ERNA-101+ Anti PD1 Ab m
Slide 12: IND Filing Status Update: GLP Safety Studies Completed with a Clean Profile
IN D Fil in g* St atu s U pd at e: G L P S a f et y S t u d i e s C o m p l e t e d w i t h a C l e a n P r o f i l e Immune activation at the tumor site, with broader changes in circulating immune cells REPEAT-DOSE TOXICOLOGY TUMORIGENICITY BIODISTRIBUTION No treatment-related No tumors or ectopic
Slide 13: Manufacturing & CMC Readiness: GMP Engineering Run Underway
Manufact uri ng & CMC R ead ine ss : Manufact uri ng Pr oces s Fi nali ze d - GMP E ngi nee ri ng Run Und er way ERNA-101 manufacturing transferred to 01 Manufacturing transferred Comparable IL-7 and IL-15 activity Potency of PD3 and PD5 as secreted SEAP Process development and analytical methods we
Slide 14: ERNA-101: Upcoming First in Human Phase 1 Study
E R N A -1 0 1 : U p c o m i n g F i r s t i n H u m a n P h a s e 1 S t u d y First-in-human, open-label study evaluating ERNA-101 (IP) in monotherapy and combination treatment STUDY PART ERNA-101 (IP) Monotherapy Dose-Escalation - Q3W SCREENING PART 1 Assessment Cycle 1 Cycle 2 Cycle 3 Cycle 4 Fol
Slide 15: Clinical Data Can Unlock Significant Value
C l i n i c a l Da t a C a n U n l o c k S i g n i f i c a n t Va l u e Selected oncology transactions demonstrate pharma investment in differentiated clinical programs UP TO UP TO UP TO $5.0B $11.4B $2.5B $3.15B upfront cash $1.2B upfront (includes $100M equity) Upfront + contingent payments Up to
Slide 16: 2026: A Year of Execution
2 0 2 6 : A Ye a r o f E xe c u t i o n Building the scientific, manufacturing and organizational foundation for clinical development PROGRESS OVER THE PAST 12 MONTHS 1 2 3 4 5 COMPLETE COMPLETE INITIATED STRENGTHENED EXECUTED FDA pre-IND IND-enabling Clinical-grade Leadership Capital and meeting st
Slide 17: Developmental Plan for Next Months; Driving ERNA-101 Toward Human Data in PROC
D e v e l o p m e n t a l P l a n f o r N ex t 2 4 M o n t h s ; D r i v i n g E R N A -1 0 1 To w a r d H u m a n D a t a i n P RO C Upcoming clinical catalysts are expected to drive value and bring new hope to patients KEY DEVELOPMENT MILESTONES Q4 2026 Q1 2027 Q4 2027 Q2 2028 IND First patient In
Slide 18: Investment Summary
Investment Summary C o m p e l l i n g Da t a . N e a r -Te r m C a t a l y st s. S i g n i f i c a n t Po t e n t i a l . NEW HOPE FOR PROC Addressing a significant unmet need in PROC 100% Current SOC shows limited survival benefit with high relapse DIFFERENTIATED CELL THERAPY Designed to turn "col
Slide 19: Providing Hope
PROVIDING HOPE We aim to change what it means to live with ovarian cancer, turning years of treatment into years of living For further details, please contact: Sanjeev Luther, President and CEO at: [email protected] ernexatx.com Nasdaq: ERNA
Ernexa Therapeutics — Investor Presentation (October 2026) on 6ix